Hyderabad-based, Aurobindo Pharma has received the approval for its chewable and dispersible Lamotrigine tablets from the US Food & Drug Administration (USFDA).
With this latest approval, the pharma major has a total of 107 approvals from USFDA in its kitty.
Lamotrigine tablets 5mg and 25mg is generic equivalent to Lamictal CD tablets 5 mg and 25 mg of GlaxoSmithKline, the compay said in a statement today. It falls under the central nervous system (CNS) segment and is indicated as adjunctive therapy for partial seizures and generalised seizures of Lennox-Gastaut syndrome in patients aged 2 years and older.
On the Bombay Stock Exchange, the company's stocks were trading at Rs 828, up 2.44 per cent at IST 1140.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app